EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms

Ghaith Abu-Zeinah, Gabriela Hobbs, Brandi N Reeves, Abdulraheem Yacoub, Joseph M Scandura

Annals of Hematology · 24.06.2026 · 105 (7)

DOI: 10.1007/s00277-026-07143-5 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Annals of Hematology, online erschienen am 24.06.2026. Verfasst von Ghaith Abu-Zeinah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Richard T. Silver MPN Center and the Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, USA. gfa2001@med.cornell.edu. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research & Treatment Fund.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Richard T. Silver MPN Center and the Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, USA. gfa2001@med.cornell.edu.
  • Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Lineberger Comprehensive Cancer Center and the Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, USA.
  • Richard T. Silver MPN Center and the Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, USA.

Förderung

  • Cancer Research & Treatment Fund

Zitieren

APA

Abu-Zeinah, G., Hobbs, G., Reeves, B. N., Yacoub, A., & Scandura, J. M. (2026). Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms. Annals of Hematology, 105(7). https://doi.org/10.1007/s00277-026-07143-5

Vancouver

Abu-Zeinah G, Hobbs G, Reeves BN, Yacoub A, Scandura JM. Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms. Annals of Hematology. 2026;105(7). doi:10.1007/s00277-026-07143-5

BibTeX
@article{AbuZeinah2026,
  author = {Abu-Zeinah, Ghaith and Hobbs, Gabriela and Reeves, Brandi N and Yacoub, Abdulraheem and Scandura, Joseph M},
  title = {Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {7},
  doi = {10.1007/s00277-026-07143-5}
}
Kostenlos starten →